Rut Porta
Girona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study.
Journal: The oncologist
Published: June 13, 2024
AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: September 06, 2022
Polycaprolactone Electrospun Scaffolds Produce an Enrichment of Lung Cancer Stem Cells in Sensitive and Resistant EGFRm Lung Adenocarcinoma.
Journal: Cancers
Published: September 08, 2021
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Journal: The Lancet. Respiratory medicine
Published: December 16, 2016
FGFR a promising druggable target in cancer: Molecular biology and new drugs.
Journal: Critical reviews in oncology/hematology
Published: August 08, 2016
Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 14, 2014
Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 08, 2014
Fatty acid synthase expression is strongly related to menopause in early-stage breast cancer patients.
Journal: Menopause (New York, N.Y.)
Published: August 29, 2013
Paraneoplastic limbic encephalitis in a male with squamous cell carcinoma of the lung.
Journal: Journal of clinical neurology (Seoul, Korea)
Published: July 02, 2013
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Journal: The Lancet. Oncology
Published: January 31, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026